bgc20-1531
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 27, 2009 (NCT00888680)
Timeline
Indications
Studied for
Mechanism of action
- Prostanoid EP4 receptorANTAGONIST
PTGER4 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- bgc20-1531
- bgc20-1531
- bgc20-1531
- n-(4-(4-(5-methoxypyridin-2-yl)phenoxymethyl)-5-methylfuran-2-carbonyl)-2-methylbenzenesulfonamide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00957983 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2009 | University of Copenhagen |
| NCT00888680 | Phase 2 | Apr 27, 2009 | BTG, University of Copenhagen |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Copenhagen | Academic/Hospital | 2 | 1 | 1 | 2009 |
| BTG | For profit | 1 | 1 | 1 | 2009 |
2 organizations
Page 1 / 1